BDH2

Summary

BDH2 (3-hydroxybutyrate dehydrogenase 2, HGNC:32389) is a protein-coding gene on chromosome 4q24, encoding Dehydrogenase/reductase SDR family member 6 (Q9BUT1). NAD(H)-dependent dehydrogenase/reductase with a preference for cyclic substrates.

Enables 3-hydroxybutyrate dehydrogenase activity and NAD binding activity. Involved in epithelial cell differentiation and fatty acid beta-oxidation. Located in cytosol.

Source: NCBI Gene 56898 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 55 total
• Druggable target: yes
• MANE Select transcript: NM_020139

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32389
Approved symbol	BDH2
Name	3-hydroxybutyrate dehydrogenase 2
Location	4q24
Locus type	gene with protein product
Status	Approved
Aliases	UCPA-OR, FLJ13261, UNQ6308, PRO20933, SDR15C1
Ensembl gene	ENSG00000164039
Ensembl biotype	protein_coding
Entrez	56898

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 18 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay

ENST00000296424, ENST00000464039, ENST00000475058, ENST00000492366, ENST00000504285, ENST00000506521, ENST00000509245, ENST00000511354, ENST00000513518, ENST00000878079, ENST00000878080, ENST00000878081, ENST00000878082, ENST00000878083, ENST00000878084, ENST00000878085, ENST00000878086, ENST00000878087, ENST00000878088, ENST00000878089, ENST00000878090, ENST00000878091, ENST00000878092, ENST00000959026

RefSeq mRNA: 1 — MANE Select: NM_020139 NM_020139

CCDS: CCDS3663

Canonical transcript exons

ENST00000296424 — 10 exons

Exon	Start	End
ENSE00001080720	103077592	103079755
ENSE00001080724	103086480	103086540
ENSE00002045522	103099783	103099834
ENSE00003534369	103096183	103096274
ENSE00003597825	103092600	103092696
ENSE00003625985	103085349	103085462
ENSE00003631930	103095203	103095281
ENSE00003655056	103091177	103091285
ENSE00003661563	103082871	103082929
ENSE00003669505	103082081	103082173

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 97.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.4188 / max 289.5386, expressed in 1753 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
53443	19.2870	1720
53444	4.1318	1385

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of stomach	UBERON:0001199	97.83	gold quality
right adrenal gland cortex	UBERON:0035827	96.94	gold quality
right adrenal gland	UBERON:0001233	96.82	gold quality
gall bladder	UBERON:0002110	96.75	gold quality
left adrenal gland cortex	UBERON:0035825	96.64	gold quality
left adrenal gland	UBERON:0001234	96.60	gold quality
left lobe of thyroid gland	UBERON:0001120	96.37	gold quality
right coronary artery	UBERON:0001625	96.28	gold quality
left ovary	UBERON:0002119	96.13	gold quality
right ovary	UBERON:0002118	96.10	gold quality
metanephros cortex	UBERON:0010533	96.10	gold quality
endocervix	UBERON:0000458	95.71	gold quality
right uterine tube	UBERON:0001302	95.71	gold quality
right lobe of thyroid gland	UBERON:0001119	95.60	gold quality
descending thoracic aorta	UBERON:0002345	95.35	gold quality
thyroid gland	UBERON:0002046	95.26	gold quality
left coronary artery	UBERON:0001626	95.20	gold quality
tibial artery	UBERON:0007610	95.18	gold quality
popliteal artery	UBERON:0002250	95.17	gold quality
body of uterus	UBERON:0009853	95.00	gold quality
ascending aorta	UBERON:0001496	94.97	gold quality
thoracic aorta	UBERON:0001515	94.95	gold quality
right lobe of liver	UBERON:0001114	94.81	gold quality
stromal cell of endometrium	CL:0002255	94.78	gold quality
aorta	UBERON:0000947	94.78	gold quality
adrenal tissue	UBERON:0018303	94.78	gold quality
left uterine tube	UBERON:0001303	94.75	gold quality
buccal mucosa cell	CL:0002336	94.66	gold quality
peripheral nervous system	UBERON:0000010	94.60	gold quality
nerve	UBERON:0001021	94.60	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	46.90
E-HCAD-10	yes	29.26
E-ANND-3	yes	23.46
E-GEOD-93593	yes	13.27
E-MTAB-6524	no	135.06
E-CURD-112	no	2.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

99 targeting BDH2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-627-3P	99.90	71.42	3316

Literature-anchored findings (GeneRIF, showing 11)

• DHRS6 is an orphan short chain dehydrogenase/ reductase enzyme (PMID:16380372)
• Data show that the ketone body metabolizing enzymes BDH1, BDH2, OXCT1 and ACAT1 were expressed at the mRNA and protein level in all glioma cell lines. (PMID:21791085)
• Iron-mediated post-transcriptional regulation of hBDH2 controls mitochondrial iron homeostasis in human cells. (PMID:22527885)
• BDH2 expression is an independent poor prognostic factor for CN-AML, with an anti-apoptotic role. Patients with high BDH2 expression have relatively shorter overall survival and a low complete response rate. (PMID:23941109)
• intracellular expression in macrophages is downregulated by stress and inflammation (PMID:25762501)
• High expression level of BDH2 is associated with esophageal squamous cell carcinoma. (PMID:26799587)
• Data demonstrated that the dysregulation of iron homeostasis in CD4(+) T cells induced by BDH2 deficiency contributes to DNA demethylation and self-reactive T cells in SLE. (PMID:29113828)
• LncRNA TP73 antisense RNA 1T (TP73-AS1) positively regulates 3-hydroxybutyrate dehydrogenase type 2 (BDH2) by regulating miR-141. (PMID:30643007)
• BDH2 expression is downregulated in nasopharyngeal carcinoma. Overexpression of BDH2 in nasopharyngeal carcinoma cells decreased the levels of intracellular iron, thereby inhibiting cell proliferation. In addition, overexpression of BDH2 reduced invasion and migration of nasopharyngeal carcinoma cells by reversing epithelial-mesenchymal transition. (PMID:31819181)
• The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. (PMID:32344823)
• BDH2 triggers ROS-induced cell death and autophagy by promoting Nrf2 ubiquitination in gastric cancer. (PMID:32605589)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	bdh2	ENSDARG00000052696
mus_musculus	Bdh2	ENSMUSG00000028167
rattus_norvegicus	Bdh2	ENSRNOG00000014490

Protein

Protein identifiers

Dehydrogenase/reductase SDR family member 6 — Q9BUT1 (reviewed: Q9BUT1)

Alternative names: (R)-beta-hydroxybutyrate dehydrogenase, 3-hydroxybutyrate dehydrogenase type 2, 4-oxo-L-proline reductase, Oxidoreductase UCPA, Short chain dehydrogenase/reductase family 15C member 1

All UniProt accessions (5): D6R9U8, D6RBF6, D6RFG2, D6RIR6, Q9BUT1

UniProt curated annotations — full annotation on UniProt →

Function. NAD(H)-dependent dehydrogenase/reductase with a preference for cyclic substrates. Catalyzes stereoselective conversion of 4-oxo-L-proline to cis-4-hydroxy-L-proline, likely a detoxification mechanism for ketoprolines. Mediates the formation of 2,5-dihydroxybenzoate (2,5-DHBA), a siderophore that chelates free cytoplasmic iron and associates with LCN2, thereby regulating iron transport and homeostasis while protecting cells against free radical-induced oxidative stress. The iron-siderophore complex is imported into mitochondria, providing an iron source for mitochondrial metabolic processes in particular heme synthesis. May act as a 3-hydroxybutyrate dehydrogenase.

Subunit / interactions. Homotetramer.

Subcellular location. Cytoplasm.

Tissue specificity. Detected in liver (at protein level).

Induction. Induced by low iron levels, and down-regulated by elevated iron levels.

Pathway. Amino-acid metabolism. Siderophore biosynthesis.

Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9BUT1-1	1	yes
Q9BUT1-2	2
Q9BUT1-3	3

RefSeq proteins (1): NP_064524* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002347	SDR_fam	Family
IPR020904	Sc_DH/Rdtase_CS	Conserved_site
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR051122	SDR_DHRS6-like	Family

Pfam: PF13561

Catalyzed reactions (Rhea), 2 shown:

• cis-4-hydroxy-L-proline + NAD(+) = 4-oxo-L-proline + NADH + H(+) (RHEA:13601)
• (R)-3-hydroxybutanoate + NAD(+) = acetoacetate + NADH + H(+) (RHEA:20521)

UniProt features (41 total): helix 14, strand 8, binding site 8, sequence conflict 4, splice variant 2, turn 2, chain 1, active site 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2AG5	X-RAY DIFFRACTION	1.84

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BUT1-F1	97.46	1.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 147 (proton acceptor)

Ligand- & substrate-binding residues (8): 16–18; 37; 58; 144; 151; 180–184; 188; 205

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-77111	Synthesis of Ketone Bodies

MSigDB gene sets: 134 (showing top): GOBP_LIPID_MODIFICATION, GOBP_FATTY_ACID_CATABOLIC_PROCESS, GOBP_EPITHELIUM_DEVELOPMENT, KOBAYASHI_EGFR_SIGNALING_24HR_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, chr4q24, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_PORPHYRIN_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_PEPTIDE_METABOLIC_PROCESS, ONKEN_UVEAL_MELANOMA_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, KOYAMA_SEMA3B_TARGETS_UP, KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION, GOBP_NONRIBOSOMAL_PEPTIDE_BIOSYNTHETIC_PROCESS

GO Biological Process (5): fatty acid beta-oxidation (GO:0006635), siderophore biosynthetic process (GO:0019290), epithelial cell differentiation (GO:0030855), heme metabolic process (GO:0042168), lipid metabolic process (GO:0006629)

GO Molecular Function (7): 3-hydroxybutyrate dehydrogenase activity (GO:0003858), 4-oxoproline reductase activity (GO:0016617), oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor (GO:0016628), NAD binding (GO:0051287), protein binding (GO:0005515), 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase activity (GO:0008667), oxidoreductase activity (GO:0016491)

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Ketone body metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	2
cellular anatomical structure	2
fatty acid catabolic process	1
fatty acid ligase activity	1
fatty acid oxidation	1
siderophore metabolic process	1
nonribosomal peptide biosynthetic process	1
secondary metabolite biosynthetic process	1
cell differentiation	1
epithelium development	1
porphyrin-containing compound metabolic process	1
pigment metabolic process	1
primary metabolic process	1
oxidoreductase activity, acting on the CH-CH group of donors	1
adenyl nucleotide binding	1
binding	1
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1
extracellular vesicle	1

Protein interactions and networks

STRING

3625 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BDH2	BDH1	Q02338	731
BDH2	ACAA1	P09110	676
BDH2	OXCT1	P55809	575
BDH2	HMGCL	P35914	540
BDH2	HMGCS2	P54868	519
BDH2	SARDH	Q9UL12	466
BDH2	HMGCS1	Q01581	428
BDH2	SLC22A17	Q8WUG5	420
BDH2	OXCT2	Q9BYC2	419
BDH2	CISD2	Q8N5K1	377
BDH2	ACAT1	P24752	375
BDH2	TMEM81	Q6P7N7	369
BDH2	ACADSB	P45954	365
BDH2	OR2M3	Q8NG83	349
BDH2	UFSP2	Q9NUQ7	342
BDH2	ACAA2	P42765	342

IntAct

17 interactions, top by confidence:

A	B	Type	Score
DIB1	BDH2	psi-mi:“MI:0915”(physical association)	0.560
BDH2	DIB1	psi-mi:“MI:0915”(physical association)	0.560
NFYC	BDH2	psi-mi:“MI:0915”(physical association)	0.560
BDH2	BDH2	psi-mi:“MI:0915”(physical association)	0.550
CFTR	BDH2	psi-mi:“MI:0915”(physical association)	0.370
CITED1	RAD21	psi-mi:“MI:0914”(association)	0.350
PCSK1	HS6ST1	psi-mi:“MI:0914”(association)	0.350
GOLGA7	TPM2	psi-mi:“MI:0914”(association)	0.350
BDH2	CKS2	psi-mi:“MI:0914”(association)	0.350
CYREN	ACOX1	psi-mi:“MI:0914”(association)	0.350
CITED1	AURKA	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
NFYC	BDH2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (43): BDH2 (Two-hybrid), BDH2 (Affinity Capture-MS), BDH2 (Affinity Capture-MS), BDH2 (Affinity Capture-MS), BDH2 (Affinity Capture-MS), BDH2 (Affinity Capture-MS), BDH2 (Affinity Capture-MS), BDH2 (Affinity Capture-MS), BDH2 (Affinity Capture-MS), BDH2 (Two-hybrid), BDH2 (Two-hybrid), VAT1 (Affinity Capture-MS), TRAPPC2 (Affinity Capture-MS), DSCC1 (Affinity Capture-MS), DHRS4 (Affinity Capture-MS)

ESM2 similar proteins: A0QYC2, B8H1Z0, C1C4R8, D4A1J4, O02691, O18404, O34896, O70351, O86034, P08074, P0A9P9, P15047, P23238, P37769, P39071, P39831, P45200, P50205, P50842, P69935, P69936, Q05528, Q15SS0, Q1JP75, Q29529, Q3KPT7, Q3T046, Q48436, Q561X9, Q7Z4W1, Q83RE8, Q8FHD2, Q8JIS3, Q8JZV9, Q8U8I2, Q8X505, Q91X52, Q91XV4, Q920N9, Q920P0

Diamond homologs: A0A067FT93, A0A165U5V5, A0A1L5BU05, A0A1L5BUG8, A0A2H3D8Y2, A0A3Q8GL18, A0A3Q8GLE8, A0A3Q8GYY4, A0A8F5SIS3, A0A8F5XX49, A0QYC2, A3F5F0, A3LZU7, A7B3K3, C1C4R8, C1DMX5, C8WGQ3, D4A1J4, D4YYG1, D4Z260, F1SWA0, F4J2Z7, F4J300, G5EGA6, H1VN83, H9BFQ0, H9BFQ1, H9BFQ2, H9XP47, K4N0V2, O31680, O80713, O80714, P07914, P07999, P0A2D1, P0A2D2, P0AET8, P0AET9, P0DOV5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1169 predictions. Top by Δscore:

Variant	Effect	Δscore
4:103082079:A:AC	donor_gain	1.0000
4:103082080:C:CC	donor_gain	1.0000
4:103082080:CTT:C	donor_gain	1.0000
4:103082082:T:TA	donor_gain	1.0000
4:103082174:C:CC	acceptor_gain	1.0000
4:103082181:C:CT	acceptor_gain	1.0000
4:103082181:C:T	acceptor_gain	1.0000
4:103082182:A:T	acceptor_gain	1.0000
4:103082870:CCT:C	donor_gain	1.0000
4:103085345:TCAC:T	donor_loss	1.0000
4:103085347:A:C	donor_loss	1.0000
4:103085460:CTC:C	acceptor_gain	1.0000
4:103085469:G:GC	acceptor_gain	1.0000
4:103091149:AT:A	donor_gain	1.0000
4:103091175:A:AC	donor_gain	1.0000
4:103091176:C:CC	donor_gain	1.0000
4:103092633:A:C	donor_gain	1.0000
4:103092636:T:TA	donor_gain	1.0000
4:103096181:A:AC	donor_gain	1.0000
4:103096182:C:CC	donor_gain	1.0000
4:103099781:A:AC	donor_gain	1.0000
4:103099782:C:CT	donor_gain	1.0000
4:103079756:C:CC	acceptor_gain	0.9900
4:103082169:CGTGC:C	acceptor_gain	0.9900
4:103082170:GTGCC:G	acceptor_loss	0.9900
4:103082172:GCCTG:G	acceptor_loss	0.9900
4:103082174:CT:C	acceptor_loss	0.9900
4:103082175:T:A	acceptor_loss	0.9900
4:103082851:A:C	donor_gain	0.9900
4:103082868:TACCT:T	donor_loss	0.9900

AlphaMissense

1613 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:103085428:C:A	K151N	0.997
4:103085428:C:G	K151N	0.997
4:103085442:A:G	Y147H	0.996
4:103085359:A:C	C174W	0.995
4:103085362:G:C	N173K	0.995
4:103085362:G:T	N173K	0.995
4:103086508:G:C	N130K	0.995
4:103086508:G:T	N130K	0.995
4:103091242:A:G	W98R	0.995
4:103091242:A:T	W98R	0.995
4:103092608:A:C	N80K	0.995
4:103092608:A:T	N80K	0.995
4:103085367:A:G	C172R	0.994
4:103082923:A:T	V180D	0.993
4:103085365:G:C	C172W	0.993
4:103085411:A:G	L157P	0.993
4:103085429:T:G	K151T	0.993
4:103086501:A:G	S133P	0.993
4:103095250:G:T	A35D	0.993
4:103079721:T:A	D240V	0.992
4:103096199:C:T	G19D	0.992
4:103079722:C:G	D240H	0.991
4:103079739:C:T	G234D	0.991
4:103085353:G:C	C176W	0.991
4:103085423:G:T	A153D	0.991
4:103085424:C:G	A153P	0.991
4:103085427:C:G	A152P	0.991
4:103091210:G:C	S108R	0.991
4:103091210:G:T	S108R	0.991
4:103091212:T:G	S108R	0.991

dbSNP variants (sampled 300 via entrez): RS1000034948 (4:103100349 C>G), RS1000039782 (4:103084209 T>G), RS1000091951 (4:103084635 C>T), RS1000131327 (4:103092696 C>A,G,T), RS1000324638 (4:103098807 T>A,C,G), RS1000711927 (4:103097516 G>A), RS1000904780 (4:103078296 G>A), RS1001137854 (4:103090881 AC>A), RS1001478167 (4:103099337 C>G), RS1001528811 (4:103099699 G>A), RS1001788340 (4:103097680 G>A), RS1001833652 (4:103092192 C>T), RS1001839192 (4:103097972 A>G), RS1001961119 (4:103077463 G>T), RS1002039162 (4:103092148 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST004946_70	Schizophrenia	3.000000e-08
GCST007269_39	Pulse pressure	6.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5169190 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	5
bisphenol A	affects expression, increases expression, affects cotreatment	3
Cyclosporine	decreases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases abundance	2
(+)-JQ1 compound	decreases expression	2
Air Pollutants	increases abundance, decreases expression	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Nickel	decreases expression	2
Tretinoin	affects cotreatment, decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
fluorotelomer sulfonic acids	increases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
lasiocarpine	decreases expression	1
triphenyl phosphate	affects expression	1
chlortoluron	decreases expression	1
butyraldehyde	decreases expression	1
ochratoxin A	increases expression	1
hydroquinone	decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
perfluorodecanoic acid	increases expression	1
perfluorooctanesulfonamide	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
perfluoro-n-heptanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
perfluorododecanoic acid	decreases expression	1
perfluorobutanesulfonic acid	increases expression	1
LDN 193189	affects cotreatment, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5218068	Binding	Binding affinity to recombinant human BDH2 assessed as shift in melting temperature by SYPRO orange dye based differential scanning fluorimetry assay	Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.